市场调查报告书
商品编码
1564658
全球细胞分析市场评估:按产品和服务、按应用、按技术、按流程、按最终用户、按地区、机会和预测(2017-2031)Cell Analysis Market Assessment, By Product and Service, By Application, By Technique, By Process, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球细胞分析市场规模预计将从 2023 年的 227.0817 亿美元增至 2031 年的 489.1348 亿美元,预计 2024-2031 年的复合年增长率为 10.07%。由于药物发现和药物开发中对细胞分析工具的需求不断增加,自动细胞计数、细胞成像、流式细胞仪等先进技术的发展,以及研发活动的快速增加,该市场正在显着增长。製药和生物技术行业。细胞分析市场预计将在预测期内进一步成长并具有更高的势头。
细胞分析辨识、测量和研究细胞结构、功能和行为的各个面向。它也可以用于发现疾病和评估治疗效果。全球细胞分析市场得到了生物医学研究进展的支持,这些研究提供了对细胞机制的详细了解,支持仔细评估功效和毒性的药物发现和开发,并透过识别疾病标记来增强临床诊断,预计将进一步增长。
生物製药公司投资增加、技术进步以及个人化医疗需求不断增长进一步推动了细胞分析市场的快速成长。例如,2024年5月,礼来公司宣布将投资90亿美元扩大印第安纳州和黎巴嫩製造工厂的生产和製造。此举旨在提高各种活性药物成分和管道药物的生产能力。这个不断发展的领域包括高通量筛选、单细胞分析、流式细胞仪和先进成像技术等多种技术。此外,药物发现在维持市场活力方面发挥关键作用。例如,2024年7月,牛津大学与生物製药投资组合公司Apollo Therapeutics Limited签署了一项药物发现研发合作协议,旨在转化牛津大学生物医学研究人员的突破性成果。
本报告研究和分析了全球细胞分析市场,提供市场规模和预测、市场动态以及主要公司的状况。
Global cell analysis market is projected to witness a CAGR of 10.07% during the forecast period 2024-2031, growing from USD 22,708.17 million in 2023 to USD 48,913.48 million in 2031. The cell analysis market has witnessed significant growth driven by increasing demand for cell analysis tools in drug discovery and development, the development of advanced technologies such as automated cell counting, cell imaging, and flow cytometry, and the surge in R&D activities in the pharmaceutical and biotechnology industry. The cell analysis market is anticipated to thrive further and have a higher momentum during the forecast period.
Cell analysis identifies, measures, and studies different aspects of cell structure, function, and behavior. It can be used to detect disease and evaluate the effectiveness of treatments. The global cell analysis market is expected to grow further, supported by developments in biomedical research that offer detailed insights into cellular mechanisms, supporting drug discovery and development that prudently assess efficacy and toxicity, and enhancing clinical diagnostics by identifying disease markers.
The cell analysis market is experiencing rapid growth, further fueled by rising investments by biopharmaceutical companies, technological advancements, and a heightened demand for personalized medicine. For instance, in May 2024, Eli Lilly and Company announced an investment of USD 9 billion to increase production and manufacturing at their Indiana and Lebanon manufacturing sites. This aims to boost the manufacturing capacity of various APIs and pipeline medicine. This evolving sector includes diverse technologies such as high-throughput screening, single-cell analysis, flow cytometry, and advanced imaging techniques. Furthermore, new drug discovery plays a crucial role in keeping the market vibrant. For instance, in July 2024, the University of Oxford and Apollo Therapeutics Limited, a portfolio biopharmaceutical company, announced the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford.
Increasing Demand for Cell Analysis Tools in Drug Discovery Drives Market Growth
The increasing demand for cell analysis in drug discovery and development drives market growth. Advanced cell screening technologies enhance research by providing precise tools for target drug discovery and validation. These techniques provide accurate data on drug effects and cellular responses, speeding drug development and reducing costs. The search for new therapies drives continued innovation in cellular diagnostic tools. Strategically utilizing advanced cell analysis tools may be effective for enhancing pipeline investments and seizing future market opportunities. For instance, in June 2024, Becton, Dickinson and Company, a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases.
Development of Advanced Technologies Positively Impact Market Growth
Technological advancements are significantly boosting growth in the cell analysis market by enhancing research capabilities and broadening application areas. Key developments like high-throughput screening, flow cell measurements, and advanced imaging techniques are at the forefront of this transformation in cell analysis. The market is expanding rapidly as researchers and clinicians seek more accurate, efficient, and scalable solutions for studying cell biology, diagnosing diseases, and developing new treatments. This growth is further fueled by a combination of artificial intelligence and machine learning, which enhance advanced data analysis and interpretation. For instance, in July 2024, Agilent Technologies Inc. launched its novel ProteoAnalyzer system at the Singapore Cell and Gene Therapy Pan Asia Summit (SCGT). This system analyzes complex protein mixtures, facilitating quicker discoveries in pharmaceuticals, biopharma, and bioengineered food ingredients.
Prevalence of Oncological Disorders in the Global Cell Analysis Market
With the high prevalence of cancer, there is a substantial need for sophisticated diagnostic tests in the form of liquid biopsies and molecular profiling that are necessary to catch the disease early on with maximum accuracy. This demand drives the development and use of sophisticated cell analysis technologies. global preclinical data in oncology supports the utility of these platforms for evaluating drug efficacy and safety. CRISPR-based approaches, multiplex assays and a gamut of cutting-edge imaging techniques are advancing traditional technologies for cell demographics. These technologies are also applied to the clinic to track disease progression and customize patient care. Initial progress in spatial omics and real-time cellular assays also extends the dimensionality of cell analysis.
For instance, in July 2024, Moffitt Cancer Center received the U.S. FDA approval for lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy, which has shown promising results in treating various types of cancers, particularly melanoma and certain other solid tumors.
North America Dominates the Global Cell Analysis Market
North America holds the largest market share in the global cell analysis market. The region boasts a strong drug discovery ecosystem, quick adoption of cutting-edge technologies, and a high rate of chronic diseases, all of which fuel the demand for advanced cell analysis solutions. Moreover, the rising cases of cancer and substantial investments from both businesses and government organizations in cell-based research also contribute to the growth of the market. For instance, according to the National Cancer Institute, in 2024, an estimated 2 million new cancer cases will be diagnosed in the United States, with 611,720 people expected to die from the disease. By 2040, the number of new cancer cases is projected to rise to 29.9 million annually, and the number of cancer-related deaths is expected to reach 15.3 million.
Future Market Scenario (2024-2031F)
The incorporation of sophisticated fiber optics with microfluidic chips for single-cell analysis is a remarkable progression that will trigger growth in the coming years within this market. This technology improves the accuracy and effectiveness of single-cell research by allowing for direct µ-resolution inspection, images, and evaluation inside the microfluidic device. Thus, it enables the collection of detailed and accurate data about cellular properties within each cell, leading to insight into inter-cellular functions and heterogeneity.
Key Players Landscape and Outlook
The global cell analysis market is quite competitive with a huge number of players at local levels as well. Regulatory approvals of company products, mergers and acquisitions, and collaborations are the most common market strategies that have been observed in recent times.
In September 2023, Agilent Technologies Inc. established a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), to enhance cell and gene therapy over the next three years. This partnership will see the installation and use of Agilent's extelligence real-time cell analyzer, Seahorse XF technology, and additional cell analysis tools at ACTRIS's largest national facility focused on developing and manufacturing cell and gene therapy in Singapore.
In July 2024, Bio-RAD Laboratories, Inc. expanded its Pioneer Antibody Discovery Platform to include rapid generation and screening of bispecific antibodies using its proprietary SpyLock Technology. This enhancement enables customers to efficiently identify and develop effective antibody combinations.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.